Novo Nordisk Stock (NVO) Good Growth and Good Value in Q1 2025

Novo Nordisk (NYSE: NVO) has emerged as a prominent player in the pharmaceutical industry, particularly in the treatment of diabetes and obesity. Despite facing challenges such as increased competition and market fluctuations, the company's robust financial performance and strategic initiatives have positioned it as a compelling investment opportunity. This article delves into Novo Nordisk's recent financial results, stock performance, growth prospects, and the risks investor should consider.

1. About Novo Nordisk

Founded on December 21, 1923, Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark. The company specializes in diabetes care, obesity treatment, and hormone replacement therapies. Its flagship products include Ozempic and Rybelsus for diabetes management, and Wegovy for obesity treatment. With a global presence in 168 countries and a workforce exceeding 77,000 employees, Novo Nordisk has established itself as a leader in the healthcare sector.

2. Novo Nordisk Financial Performance

In Q1 2025, Novo Nordisk reported revenue of $11.31 billion, marking a 19.72% increase from $9.45 billion in Q1 2024. Earnings per share (EPS) for the quarter stood at $0.95, up 15.85% from $0.82 in the same period last year. On a trailing twelve months (TTM) basis, revenue reached $43.94 billion, a 24.37% rise from $35.33 billion in Q1 2024. TTM EPS was $3.40, reflecting an 18.06% increase from $2.88. Free cash flow per share (TTM) surged by 48.47% to $2.42, compared to $1.63 in the previous year.

The company's profitability metrics are impressive, with a gross profit margin of 84.65% and a net profit margin of 34.51%. Return on assets (ROA) stands at 23.29%, while return on equity (ROE) is a remarkable 88.12%. The debt-to-equity ratio is 0.86, indicating a balanced capital structure.

Over the past five years, the company has consistently grown its business. Revenue has increased at a 22.7% CAGR, net income at 23.9%, and free cash flow at 13.5%.

3. Novo Nordisk 2025 Financial Forecast

Looking ahead, analyst project continued growth for Novo Nordisk. Analysts forecast revenue for 2025 to be $51.11 billion, a 26.2% increase from 2024's $40.33 billion. EPS is projected to rise to $3.97, up 25.85% from $3.14 in 2024. The consensus price target is $92.20 with Strong Buy rating, suggesting a potential upside of 40.19% from the current price.

4. NVO Stock Price Performance and Valuation

At the time this article is written, Novo Nordisk's stock price is $66.56. Over the past year, the stock has declined by 48.8%, underperforming the S&P 500, which increased by 8.5% in the same period. However, over the past five years, NVO has appreciated by 105.8%, outperforming the S&P 500's 97.1% gain.

The stock offers a dividend yield of 2.45%. Valuation metrics include a TTM price-to-sales (P/S) ratio of 6.79 and a forward P/S of 5.82. The TTM price-to-earnings (P/E) ratio is 19.7, with a forward P/E of 16.56. The price-to-free cash flow (P/FCF) TTM ratio is 24.96.

If we look at the valuation over the past five years, Novo Nordisk is trading at a lower valuation compared to its five-year average. The company's forward P/S is below its average of 9.77, its forward P/E is below the average of 28.76, and its forward P/FCF is below the average of 24.16. The recent stock decline makes Novo Nordisk more compelling, as it has driven down the valuation.

Despite the recent stock price decline, Novo Nordisk's strong financial performance and growth prospects suggest that the current valuation presents a potential buying opportunity for long-term investors.

5. Novo Nordisk Growth Potential

Novo Nordisk's growth is driven by its leading position in the diabetes and obesity treatment markets.

• Strong Obesity Product Growth
  Novo Nordisk's diabetes and obesity care segment was the primary growth engine in Q1 2025, with sales increasing by 21% in Danish kroner to DKK 73.5 billion (approximately $11.2 billion) at constant exchange rates. Within this segment, obesity care sales surged dramatically by 65% to DKK 18.4 billion, reflecting strong demand for weight management treatments, particularly Wegovy, the company's flagship GLP-1 receptor agonist for obesity. Wegovy's sales alone rose by 83% year-on-year, reaching DKK 17.36 billion, although this figure slightly missed analyst expectations due to slower-than-anticipated market penetration in the U.S.
  With the FDA recently removing semaglutide injectables from its shortage list, the company expects a decline in compounded GLP-1 use during the second half of 2025, with those sales potentially shifting to Novo Nordisk's branded products.
• Market Position and Patient Reach
  Novo Nordisk has significantly expanded its patient base, now serving nearly 46 million individuals with diabetes and obesity treatments globally, representing an increase of almost 4 million patients from the previous year. This expanding reach demonstrates the growing adoption of the company's treatments and its increasing market penetration.
  The company has also strengthened its presence in the United States, its largest market, with a workforce now exceeding 10,000 full-time employees and substantial investments in manufacturing facilities. These investments position Novo Nordisk to better meet growing demand and capitalize on market opportunities.
• Pipeline and Product Expansion
  The completion of the pivotal REDEFINE 2 trial for CagriSema, Novo Nordisk's next-generation obesity treatment, represents a significant milestone, with regulatory submission on track for early 2026. This advanced therapy could potentially strengthen the company's leadership position in the obesity treatment market.
  Additionally, the U.S. FDA has accepted the application for Wegovy 2.4 mg for treating metabolic dysfunction-associated steatohepatitis (MASH) and granted it priority review. This potential label expansion could substantially broaden the addressable market for Wegovy beyond weight management.

6. Risks to Consider

While Novo Nordisk looks like a compelling investment, investors should be aware of potential risks.

• Reduced Sales Growth Outlook
  Despite an 18% sales increase and 20% rise in operating profit in Q1 2025, Novo Nordisk lowered its full-year sales growth guidance to 13–21% at constant exchange rates, down from the previous 16–24% forecast. This revision is mainly due to intensified competition from compounded, unbranded semaglutide-based weight-loss drugs in the U.S., which are cheaper and have quickly gained market share, limiting the uptake of Novo Nordisk’s branded GLP-1 products.
  Although Wegovy sales grew 83% year-over-year to about DKK 17.4 billion, this was slightly below expectations and reflected some market share loss to competitors like Eli Lilly’s Zepbound, as well as destocking effects. The U.S., Novo Nordisk’s largest market with 57% of sales, saw 17% growth in Q1, but the company noted that Wegovy destocking and compounded drug competition weighed on growth momentum despite the FDA resolving earlier drug shortages.
• Market Share Loss to Competitors
  Novo Nordisk’s Wegovy has experienced growing competition from Eli Lilly’s Zepbound in the U.S. obesity treatment market, leading to a notable loss of market share. Zepbound, a dual GIP and GLP-1 receptor agonist, has demonstrated superior clinical efficacy, with studies showing patients on Zepbound achieving around 20.2% average weight loss compared to Wegovy’s approximately 13.7–15%, making it a more attractive option for healthcare providers and patients seeking effective weight management.
  Additionally, Zepbound has gained FDA approval for multiple indications, including severe obstructive sleep apnea, broadening its patient base and increasing its market appeal. Eli Lilly’s substantial investments in manufacturing capacity and strategic marketing have further strengthened Zepbound’s position, enabling it to surpass Wegovy in new U.S. prescriptions and intensifying the competitive landscape for Novo Nordisk. This shift introduces uncertainty to Novo Nordisk’s growth trajectory in the obesity segment, as it faces pressure to defend its market share amid evolving treatment preferences, pricing negotiations, and reimbursement dynamics.
• Pipeline and Development Risks
  Novo Nordisk’s pipeline includes promising next-generation obesity treatments, such as CagriSema-a combination of semaglutide and an amylin analogue-which aims to improve weight loss outcomes beyond current GLP-1 therapies.
  However, the company faced a setback with disappointing late-stage trial results for CagriSema, which temporarily impacted its stock value and underscored the inherent risks in drug development timelines and clinical efficacy.

Read More: MercadoLibre Stock (MELI) Strong Growth and Good Value in Q1 2025

Conclusion

Novo Nordisk's robust financial performance, strategic initiatives, and strong position in growing markets make it an attractive investment opportunity. While potential risks exist, the company's proactive approach to addressing challenges and its commitment to innovation position it well for sustained growth. Investors seeking exposure to the healthcare sector may find Novo Nordisk a compelling addition to their portfolios.